Aims To identify the predictors of CD when presented with LD.

Methods 215 LD patients had undergone prospective and systematic evaluation for CD and other recognised associations.

The gold-standard diagnosis of CD was based upon the presence of HLA-DQ2 and/or DQ8, persistence or progression of LD following a gluten-free diet, symptomatic improvement on a gluten-free diet, and no alternate cause found.

Binary logistic regression models, adjusting for age and gender, were subsequently performed to compare presenting variables between CD and non-CD cases, and to determine their sensitivity, specificity, positive and negative predictive values (PPV and NPV).

Results CD was diagnosed in 47 cases (22%) and non-CD in 168 cases (78%). There was no statistical difference in demographics, clinical symptoms (i.e. diarrhoea, weight loss, abdominal pain), anaemia or haematocrits between the CD and non-CD group.

Patients with CD, in comparison to non-CD, were significantly more likely to have a positive family history of CD (21.3% vs. 3.6%, OR 6.8; PPV 62.5%, NPV 81.4%, specificity 96.4%), positive HLA-DQ2 status (100% vs. 49.4%; PPV 36.2%, NPV 100%, specificity 50.6%), and presence of endomysial anti-body [EMA] (49% vs. 0.6%, OR 159; PPV 96%, NPV 87%, specificity 99.4%); all p < 0.001.

A normal tissue transglutaminase antibody (TTG) level was seen in 29.8% CD and 82.7% non-CD cases (OR 0.086, p < 0.001; PPV 91%). There was no difference in the prevalence of TTG levels 1–2 x upper limit of normal (ULN) between the groups (29.8% CD vs. 14.3% non-CD; PPV 38%); however, TTG levels between 3–20xULN were significantly more prevalent in the CD group (31.9% vs. 3%; PPV 66.6% >87.5%), whilst a TTG > 20 x ULN was exclusive to CD (8.5% vs. 3%; PPV 66.6%) (OR 0.086, p < 0.001; PPV 100%).

Conclusion At the outset, only the presence of positive EMA or TTG > 20 x ULN are highly predictive and specific for CD. However, as they have limited sensitivities, most patients with LD require further work-up prior to diagnostic confirmation.

Disclosure of Interest None Declared.

PTU-152 PEPSIN IN SALIVA FOR THE DIAGNOSIS OF GASTRO-ESOPHAGEAL REFLUX DISEASE


Introduction Current diagnostic tests for GORD have moderate sensitivity/specificity and can be invasive and expensive. Pepsin determination in saliva has been proposed as an “office-based” method for GORD diagnosis. The aims of this study were to establish normal values of salivary pepsin in a large cohort of healthy asymptomatic subjects and to determine its value to discriminate patients with reflux-related symptoms (GORD, hyper-sensitive oesophagus) from functional heartburn.

Methods 100 asymptomatic controls and 111 patients with heartburn underwent MII-pH monitoring and simultaneous salivary pepsin determination on waking, after lunch and dinner. Cut off value for pepsin positivity was 16 ng/ml. Patients were divided into GORD (increased acid exposure time (AET) n = 58); Hypersensitive Oesophagus (HO) (normal AET and + SAP), n = 26) and Functional Heartburn (FH) (normal AET and – SAP n = 27). Multiple group comparisons were performed using one-way ANOVA followed by with Tukey’s Test for Gaussian distributed data and the Kruskall-Wallis Test with Dunns comparison for non-Gaussian data. Receiver Operator Characteristic curves were constructed to determine and compare the sensitivity and specificity of different pepsin cut-off concentrations.

Results 1/3 of asymptomatic subjects had pepsin in saliva at low concentration (0(0–59) ng/ml). Patients with reflux-related symptoms (GORD and HO) had higher prevalence (77–89%) and pepsin concentration than controls (HO, 237(52–311) ng/ml and GORD, 121(29–252) ng/ml) (p < 0.05). Patients with FH had low prevalence (33%) and concentration of pepsin in saliva (0 (0–40) ng/ml). The area under the receiver operating characteristic curve had a value of 0.8034 +/-0.04 (95% confidence interval 0.719 to 0.8873, p < 0.0001). A positive test had 77.6% sensitivity and 63.2% specificity for diagnosis of GORD/HO. When all saliva samples were negative, there was 80% probability that symptoms were not due to reflux (FH). One positive sample with >210 ng/ml pepsin suggested the presence of GORD/HO with 95% probability.

Conclusion In patients with symptoms suggestive of GORD, salivary pepsin can be used to confirm or reject the diagnosis before empirical PPI treatment. This may lessen the use of unnecessary anti-reflux therapy and the need for further invasive and expensive diagnostic methods.

Surprisingly in 53% of NDBE tissue samples we identified clonal expansion of cells (>10% mutant fraction) harbouring mutations in one or more of 13/15 of these putative driver genes. No difference in the frequency of mutation of these genes was observed between any of the disease stages studied. TP53 mutations clearly delineate between HGD/OAC and benign NDBE (p < 0.001). Whilst SMAD4 mutations are only observed in OAC (p < 0.001) demonstrating for the first time a clear genetic difference between the two.

Conclusion Mutagenic processes active in OAC are also active in the earliest stages of BE. Recurrent driver mutations identified in cancer may be acquired very early in the disease and may provide little or no progression advantage. Molecular diagnostic approaches must account for this.

Disclosure of Interest None Declared.

**REFERENCES**